Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF): Answers or More Questions?
Authors: Julie M. Vose, Philip J. Bierman, James O. Armitage
Journal: Annals of Internal Medicine (1992)

Editorials1 February 1992Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF): Answers or More Questions?Julie M. Vose, MD, Philip J. Bierman, MD, James O. Armitage, MDJulie M. Vose, MDSearch for more papers by this author, Philip J. Bierman, MDSearch for more papers by this author, James O. Armitage, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-116-3-261 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptAlthough tremendous progress has been made in the treatment of malignant lymphomas, patients who fail to achieve a complete remission with standard chemotherapy or who relapse after an initial complete remission have a 2-year disease-free survival of less than 5% with routine "salvage" chemotherapy (1-3). In an attempt to overcome the intrinsic resistance of the malignant cells, high-dose chemotherapy and autologous bone marrow transplantation have been used in this patient population. Data from several studies conducted in patients with relapsed lymphoma undergoing high-dose chemotherapy and autologous bone marrow transplantation indicate a 2-year disease-free survival ranging from 20% to 45% (4-6)....References1. CabanillasHagemeisterMcLaughlinVelasquezRiggsFuller FFPWSL. Results of MIME salvage regimen for recurrent or refractory lymphoma. J Clin Oncol. 1987;5:407-12. CrossrefMedlineGoogle Scholar2. VelasquezCabanillasSalvadorMcLaughlinFridrikTucker WFPPMS. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose ara-C and dexamethasone (DHAP). Blood. 1988;71:117-22. CrossrefMedlineGoogle Scholar3. CabanillasHagemeisterBodeyFreireich FFGE. IMVP-16: an effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapy. Blood. 1982;60:693-97. CrossrefMedlineGoogle Scholar4. PhilipArmitageSpitzerChauvinJagannathCahn TJGFSJ. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N Engl J Med. 1987;316:1493-8. CrossrefMedlineGoogle Scholar5. FreedmanTakvorianAndersonMauchRabinoweBlake ATKPSK. Autologous bone marrow transplantation in B-cell non-Hodgkin's lymphoma: very low treatment-related mortality in 100 patients in sensitive relapse. J Clin Oncol. 1990;8:784-91. CrossrefMedlineGoogle Scholar6. PetersenAppelbaumHillRisherBigelowSanders FFRLCJ. Autologous marrow transplantation for malignant lymphoma: a report of 101 cases from Seattle. J Clin Oncol. 1990;8:638-47. CrossrefMedlineGoogle Scholar7. ChamplinGale RR. Early complications of bone marrow transplantation. Semin Hematol. 1984;21:101-8. MedlineGoogle Scholar8. GulatiBennett SC. Granulocyte-macrophage colony-stimulating factor (GM-CSF) as adjunct therapy in relapsed Hodgkin disease. Ann Intern Med. 1992;116:177-82. LinkGoogle Scholar9. AdvaniChaoHorningBlumeAhnLamborn RNSKDK. Granulocyte-macrophage colony-stimulating factor (GM-CSF) as an adjunct to autologous hemopoietic stem cell transplantation for lymphoma. Ann Intern Med 1992;116:183-9. LinkGoogle Scholar10. NemunaitisRabinoweSingerBiermanVoseFreedman JSJPJA. Recombinant granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for lymphoid cancer. N Engl J Med. 1991;324:1773-8. CrossrefMedlineGoogle Scholar11. GorinCoiffierPico NBJ. Granulocyte-macrophage colony-stimulating factor (GM-CSF) shortens aplasia duration after autologous bone marrow transplantation (ABMT) in non-Hodgkin's lymphoma. A randomized placebo-controlled double-blind study. Blood. 1990;76(Suppl l):542a. Google Scholar12. LinkBoogaertsCarellaFerrantGadnerGorin HMAAHN. Recombinant human granulocyte-macrophage colony stimulating factor (RH-GM-CSF) after autologous bone marrow transplantation for acute lymphoblastic leukemia and non-Hodgkin's lymphoma: a randomized double blind multicenter trial in Europe. Blood. 1990;76(Suppl 1):152a. Google Scholar13. ReeceBarnettConnorsFaireyKlingemennO'Reilly DMJRHS. Intensive therapy with cyclophosphamide, BCNU, VP-16-213 ± Cisplatin (CBV ± P) and autologous bone marrow transplantation (AuBMT) for advanced Hodgkin's disease (HD): Outcome and prognostic factors in 90 patients. Blood 1991;78(Suppl 1):273a. Google Scholar14. BiermanJagannathArmitageSpitzerVoseCabanillas PSJGJF. High-dose cyclophosphamide, carmustine, and etoposide in Hodgkin disease: Follow-up of 128 patients. Proceedings of the Fifth International Autologous Bone Marrow Transplantation Symposium. 1991;5:519-27. Google Scholar15. ReedArmitageVaughanVoseBiermanKessinger EJWJPA. The effects of continuous infusion GM-CSF in adult patients receiving high-dose chemotherapy and autologous bone marrow transplant. Proceedings of the Keystone Bone Marrow Transplantation Symposium [In press]. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: University of Nebraska Medical Center Omaha, NE 68198-3330 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByHematopoietic cytokines current use in cancer therapy 1 February 1992Volume 116, Issue 3Page: 261-262KeywordsBone marrow transplantationCellsChemotherapyDisease free survivalGranulocyte macrophage colony stimulating factorHigh-dose chemotherapyLymphoma Issue Published: 1 February 1992 PDF DownloadLoading ...